Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

@article{LotufoNeto1999MetaAnalysisOT,
  title={Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression},
  author={Francisco Lotufo-Neto and Madhukar H. Trivedi and Michael E. Thase},
  journal={Neuropsychopharmacology},
  year={1999},
  volume={20},
  pages={226-247}
}
The reversible inhibitors of monoamine oxidase type A (RIMAs) are a newer group of antidepressants that have had much less impact on clinical psychopharmacology than another contemporary class of medications, the selective serotonin reuptake-inhibitors (SSRIs). The RIMAs agents are distinguished from the older monoamine oxidase inhibitors (MAOIs) by their selectivity and reversibility. As a result, dietary restrictions are not required during RIMA therapy, and hypertensive crises are quite rare… CONTINUE READING
33 Citations
130 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 130 references

Brofaromine. Insight into the nature of drug development

  • HP Volz, CH Gleiter, M Struck, HJ Möller
  • CNS Drugs
  • 1995
Highly Influential
14 Excerpts

Comparison of the efficacy of moclobemide and fluvoxamine in elderly patients with a severe depressive episode

  • JP Bocksberger, JP Gachoud, J Richard, P Dick
  • Eur Psychiatry
  • 1993
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…